Pharmacological Approach for Symptomatic Nonsustained Ventricular Tachycardia
Ida Obeso-Martinez1, Farshad Raissi
1Author Affiliations: University of San Diego, San Diego, California (Dr Colio); Imperial Cardiac Center, Imperial, California (Dr Obeso-Martinez); and University of California San Diego, San Diego (Dr Raissi).
Nonsustained ventricular tachycardia (NSVT) is a common heart rhythm issue. This case discusses its typical presentation and treatment in stable patients.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Nonsustained ventricular tachycardia (NSVT) is a frequent arrhythmia linked to various cardiac conditions like heart failure and coronary artery disease.
- While often asymptomatic, NSVT can manifest with symptoms such as palpitations, near-syncope, dizziness, chest pain, and dyspnea.
Purpose of the Study:
- To detail the common clinical presentation of stable NSVT.
- To outline the pharmacological management strategies for patients diagnosed with stable NSVT.
Main Methods:
- Diagnosis often necessitates prolonged cardiac monitoring, mobile cardiac telemetry (MCT), or internal loop recorders, as standard ECG may not capture the arrhythmia upon emergency department (ED) arrival.
- Case study approach focusing on typical patient presentation and subsequent treatment.
Main Results:
- NSVT diagnosis can be challenging due to intermittent nature, often requiring advanced monitoring beyond initial ECG.
- Elevated troponin levels can occur due to demand ischemia in some NSVT cases.
Conclusions:
- Effective identification of NSVT relies on extended cardiac monitoring.
- Pharmacological interventions are key in managing stable NSVT presentations.
Related Concept Videos
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...


